UCLA researchers have identified a promising strategy to make a new class of targeted cancer therapies more effective against one of the deadliest forms of prostate cancer, potentially overcoming treatment resistance that has limited their success.

About the Study: Does the addition of high-dose vitamin D to standard treatment improve progression-free survival in patients with metastatic colorectal cancer? In this multicenter, double-blind phase 3 randomized clinical trial in patients with previously untreated metastatic colorectal cancer, the addition of high-dose vitamin D to standard treatment did not significantly improve progression-free survival compared with standard-dose vitamin D (median progression-free survival, 11.8 months vs 10.3 months, respectively). High-dose vitamin D did not improve progression-free survival in patients with metastatic colorectal cancer.

A new Houston Methodist-led study reports a breakthrough in understanding why some patients with metastatic breast cancer fail to respond to a common and important early-stage treatment.

VCU Massey Comprehensive Cancer Center was recently awarded a $2.7 million Worta McCaskill-Stevens K12 grant from the National Institutes of Health (NIH). The five-year grant will allow Massey to mentor promising, multidisciplinary, early-stage clinical investigators in the conception, development, and implementation of innovative cancer prevention and control studies designed to optimize participation by cancer survivors and individuals most at risk for cancer throughout Virginia.VCU Massey Comprehensive Cancer Center was recently awarded a $2.7 million Worta McCaskill-Stevens K12 grant from the National Institutes of Health (NIH). The five-year grant will allow Massey to mentor promising, multidisciplinary, early-stage clinical investigators in the conception, development, and implementation of innovative cancer prevention and control studies designed to optimize participation by cancer survivors and individuals most at risk for cancer throughout Virginia.

Liver cancer often returns after surgery, but doctors currently lack reliable tools to identify which patients face the greatest risk.

Singapore researchers have uncovered two distinct ways that hepatocellular carcinoma, the most common type of liver cancer, recurs at the molecular level and have used these insights to develop a new machine-learning prediction tool.

Validated across independent patient groups, the tool leverages on both genomics and clinical data and outperformed the commonly used TNM staging system – which assesses disease stage based on tumour burden alone – in predicting recurrence risk and could aid surveillance, treatment decision-making and clinical trials.

New research reveals that cells of the same chronological age can follow dramatically different biological aging paths, offering new insights into cancer, neurodegeneration, and the fundamental biology of aging. Rather than aging uniformly, tissues become a mosaic of biologically younger and older cells, with some individual cells aging much faster than others—a discovery that could reshape how scientists understand aging and the earliest origins of age-related disease.